SCHEMBL9072811

SCHEMBL9072811

O=C(Nc1nn[nH]n1)c1ccc(CN(C(=O)Nc2nc3ccc(SC(F)(F)F)cc3s2)c2ccc(C3CCCCC3)cc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
GCGR P47871 19/20 0.51
GIPR P48546 10/20 0.51
GCG P01275 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2663472 0.95 GCGR (0.52) GCGRGIPRGCG
SCHEMBL4095902 0.89 GCGR (0.53) GCGRGIPRGCG
SCHEMBL4097365 0.89 GCGR (0.55) GCGRGIPRGCG
SCHEMBL9072792 0.88 GCGR (0.52) GCGRGIPRGCG
SCHEMBL2663603 0.88 GCGR (0.52) GCGRGIPRGCG
SCHEMBL2663364 0.88 GCGR (0.52) GCGR
SCHEMBL2663613 0.88 GCGR (0.51) GCGRGIPRGCG
SCHEMBL2663468 0.88 GCGR (0.51) GCGRGIPRGCG
SCHEMBL2663477 0.88 GCGR (0.51) GCGRGIPRGCG
SCHEMBL9072771 0.87 GCGR (0.54) GCGRGIPRGCG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 US disclosed
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 US disclosed
WO-2000069810-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2000-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists GLP1R, GPR119, GCGR GCGR 3/4885GIPR 4/4885GCG 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.